- Home
- CUE vs FSEA Comparison
CUE vs FSEA Comparison
Compare CUE & FSEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CUE | FSEA |
|---|---|---|
| Founded | 2014 | 1890 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 56.1M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUE | FSEA |
|---|---|---|
| Price | $0.42 | $12.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 249.2K | 5.3K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,100,000.00 | ★ $14,753,000.00 |
| Revenue This Year | $36.58 | N/A |
| Revenue Next Year | $32.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 29.53 |
| 52 Week Low | $0.47 | $9.51 |
| 52 Week High | $1.75 | $13.00 |
Technical Indicators
Market Signals| Indicator | CUE | FSEA |
|---|---|---|
| Relative Strength Index (RSI) | 22.60 | 54.05 |
| Support Level | $0.47 | $12.12 |
| Resistance Level | $0.51 | $12.42 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 0.00 | 33.74 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.